Chrissy's Profit Paradise

[Hedge Starz]

VistaGen Therapeutics $VSTA Fact Sheet:

http://www.vistagen.com/

http://investorshub.advfn.com/boards/board.aspx?board_id=22070

VistaGen Therapeutics IR Kit http://www.missionir.com/clientsummary/vsta.pdf

http://finance.yahoo.com/q?s=VSTA.OB

http://www.otcmarkets.com/stock/VSTA/quote

http://www.vistagen.com/Theme/VistaGen/files/media/Vistagen_FactSheet_Feb2011.pdf (Feb 2011)

VistaGen Therapeutics, Inc. is a biotechnology company focused on using proprietary stem cell technologies for drug rescue.
Our integrated stem cell biology platform, Human Clinical Trials in a Test Tube™, is designed to provide an early indication, or prediction, of the potential cardiac toxicity of drug candidates before they are ever tested in humans.

Our stem cell technology is designed to identify new, safer, variants of promising drug candidates. These candidates have been previously “put on the shelf” by pharmaceutical companies due to toxicity concerns, despite positive efficacy data signaling their potential therapeutic benefits. Our goal is to build a diverse drug pipeline of “drug rescue variants” that are as effective as the original drug candidates but without the toxicity that caused them to be put on the shelf in the first place.

Technology: http://www.vistagen.com/technology/default.aspx

Product Line: http://www.vistagen.com/products/Clinical-Trials-in-a-Test-Tube/default.aspx

Business Model: http://www.vistagen.com/business-model/default.aspx

Related Research Videos at Toronto’s McEwen Center:

http://www.vistagen.com/Theme/VistaGen/files/flash/kellerv%20in%20the%20news%20edited.wmv

Corporate Objective Per 10Q:
“We are a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy.
Drug rescue involves the combination of human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of promising small molecule drug candidates that pharmaceutical companies have discontinued during preclinical development ("put on the shelf") due to heart or liver toxicity. We anticipate that our stem cell technology platform, Human Clinical Trials in a Test Tube, will allow us to assess the heart and liver toxicity profile of new drug candidates with greater speed and precision than nonclinical in vitro techniques and technologies currently used in the drug development process. Our drug rescue model is designed to leverage both the pharmaceutical company's prior investment in preclinical development of promising drug candidates put on the shelf and the predictive toxicology and drug development capabilities of our Human Clinical Trials in a Test Tube tm platform.”

http://biz.yahoo.com/e/110822/vsta.ob10-q.html

“With mature heart cells produced from stem cells, we have developed CardioSafe 3D, a three-dimensional ("3D") bioassay system. We believe CardioSafe 3D is capable of predicting the in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates before they are tested in humans. Our immediate goal is to leverage CardioSafe 3D to generate and monetize a pipeline of small molecule drug candidates through drug rescue collaborations. We intend to expand our drug rescue capabilities by introducing LiverSafe 3D, a human liver cell-based toxicity and metabolism bioassay system.
In parallel with our drug rescue activities, we plan to advance pilot preclinical development of cell therapy programs focused on heart, liver and cartilage repair, as well as autologous bone marrow transplantation. Each of these cell therapy programs is based on the proprietary differentiation and production capabilities of our Human Clinical Trials in a Test Tube tm platform.
With grant funding from the U.S. National Institutes of Health ("NIH"), we are also developing AV-101, an orally available small molecule prodrug candidate aimed at the multi-billion dollar neurological disease and disorders market. AV-101 is currently in Phase I development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. Neuropathic pain affects approximately 1.8 million people in the U.S. alone. To date, we have been awarded over $8.3 million of grant funding from the NIH for preclinical and Phase I clinical development of AV-101.
Our plan is to acquire rights to drug candidates that pharmaceutical companies have put on the shelf due to heart or liver toxicity, collaborate with medicinal chemistry researchers, and generate a pipeline of proprietary small molecule drug rescue variants which may be as effective and commercially promising as the pharmaceutical company's original (toxic) drug candidate but without the toxicity that caused it to be put on the shelf. We plan to have economic participation rights in each drug generated in connection with our drug rescue programs.”
Financial Highlights: “Revenues were $554,616 for the quarter ended June 30, 2011, a decrease from $733,921 for the quarter ended June 30, 2010. The decrease is the result of a decrease in NIH grant revenue of $173,146 and a decrease in grant revenue from the California Institute of Regenerative Medicine ("CIRM") of $47,258. The decreases in grant revenue were due to the rescheduling of certain grant-funded work to future periods. The decreases were partly offset by an increase in other NIH grant revenue of $41,099.”

Warrants: “Each warrant entitles the holder to purchase one-fourth (1/4) of one share of our common stock at an exercise price of $2.50 per share.”

Share Structure:
Shares Outstanding 15,241,904 a/o Aug 22, 2011
Float 10,141,904 a/o Dec 31, 2010
Authorized Shares 4,00000,000 a/o Jun 30, 2011

Management:

Shawn Singh, JD, Chief Executive Officer, Director
Mr. Singh has nearly 20 years of experience working with public and private biotechnology and pharmaceutical companies. He formerly served as Managing Principal of Cato BioVentures, a life science venture capital firm, and as Chief Business Officer of Cato Research Ltd., a global contract research and development organization. Mr. Singh has also served in senior management roles at Echo Therapeutics (OTCBB: ECTE) as President, and SciClone Pharmaceuticals (Nasdaq: SCLN) as Chief Business Officer. Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP. Mr. Singh is a member of the State Bar of California.

Ralph Snodgrass, PhD, President, Chief Scientific Officer, Director
Dr. Snodgrass founded VistaGen in 1998. He has over 13 years of experience in senior biotechnol¬ogy management, including as Chief Scientific Officer of Progenitor, Inc. He has more than 10 years of research experience as a professor at the Lineberger Comprehensive Cancer Center, University North Carolina Chapel Hill School of Medicine, and as a member of the Institute for Immunology, Basel, Switzerland. Dr. Snodgrass is a past Board Member of the Emerging Company Section of the Biotechnology Industry Organiza¬tion (BIO), and is a published and recognized pioneering expert in stem cell biology with more than 20 years experience in the uses of stem cells as biological tools for drug discovery and development.

Gordon Keller, PhD, Chairman, Scientific Advisory Board
Dr. Keller, recently named a “Top 25 Transforma¬tional Canadian” for his stem cell research, was appointed Director of the McEwen Centre for Regenerative Medicine of the University Health Network in Toronto in 2007. He has published more than 100 papers and is named on five pat¬ents. Dr. Keller is a former president of the Inter¬national Society for Stem Cell Research. He is the Canada Research Chair in Embryonic Stem Cell Biology, a Professor at the University of Toronto and a Senior Scientist in the Division of Stem Cell and Developmental Biology at the Ontario Cancer Institute. Dr. Keller was a Professor in the Depart¬ment of Gene and Cell Medicine at the Mt. Sinai School of Medicine in New York where he was described by New York Magazine as one of “six doctors New York can’t lose.”

Franklin Rice, MBA, Chief Financial Officer
Genencor International, Bechtel Group
Transfer Agent:
Holladay Stock Transfer
2939 N. 67th Place
Scottsdale, AZ, 85251
480-481-3940

Investor & Media Contact
Shawn K. Singh, JD
Chief Executive Officer
VistaGen Therapeutics, Inc.
T: 650-244-9990
E: [e-mail]